Buchumschlag

What's new in consolidation therapy in AML?

Intensive induction chemotherapy followed by postremission treatment with either high-dose cytarabine-based regimens, autologous or allogeneic hematopoietic stem cell transplantation is still recognized as the main road toward cure in acute myeloid leukemia (AML). Pretreatment risk classification re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Schlenk, Richard Friedrich (VerfasserIn) , Jaramillo Segura, Sonia (VerfasserIn) , Müller-Tidow, Carsten (VerfasserIn)
Dokumenttyp: Article (Journal) Kapitel/Artikel
Sprache:Englisch
Veröffentlicht: 2019
In: ScienceDirect. [Elsevier journals]. [Cell Press journals collection]
Year: 2018, Jahrgang: 56, Heft: 2, Pages: 96-101
DOI:10.1053/j.seminhematol.2018.08.005
Online-Zugang:Verlag, Volltext: https://doi.org/10.1053/j.seminhematol.2018.08.005
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0037196318301069
Volltext
Verfasserangaben:Richard F. Schlenk, Sonia Jaramillo, Carsten Müller-Tidow

MARC

LEADER 00000caa a2200000 c 4500
001 1687942323
003 DE-627
005 20230427215405.0
007 cr uuu---uuuuu
008 200121r20192018xx |||||o 00| ||eng c
024 7 |a 10.1053/j.seminhematol.2018.08.005  |2 doi 
035 |a (DE-627)1687942323 
035 |a (DE-599)KXP1687942323 
035 |a (OCoLC)1341298680 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Schlenk, Richard Friedrich  |d 1965-  |e VerfasserIn  |0 (DE-588)129025380  |0 (DE-627)387778004  |0 (DE-576)297454102  |4 aut 
245 1 0 |a What's new in consolidation therapy in AML?  |c Richard F. Schlenk, Sonia Jaramillo, Carsten Müller-Tidow 
264 1 |c 2019 
300 |a 6 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Available online 29 August 2018 
500 |a Gesehen am 21.01.2020 
520 |a Intensive induction chemotherapy followed by postremission treatment with either high-dose cytarabine-based regimens, autologous or allogeneic hematopoietic stem cell transplantation is still recognized as the main road toward cure in acute myeloid leukemia (AML). Pretreatment risk classification remains a key determinant of type and intensity of post-remission therapy. Still, high-dose cytarabine-based consolidation therapy is a cornerstone of postremission therapy with some recent adjustments regarding dosage and schedule. Current approvals of midostaurin, gemtuzumab ozogamicin, CPX-351, and ivosidenib as well as enasidenib comprise induction as well as consolidation therapy. In recent years measurable residual disease assessment is increasingly used to dynamically fine tune treatment during postremission treatment. 
534 |c 2018 
700 1 |a Jaramillo Segura, Sonia  |e VerfasserIn  |0 (DE-588)1149855606  |0 (DE-627)1010162772  |0 (DE-576)496412213  |4 aut 
700 1 |a Müller-Tidow, Carsten  |d 1968-  |e VerfasserIn  |0 (DE-588)1015101798  |0 (DE-627)705330230  |0 (DE-576)351197893  |4 aut 
773 0 8 |i Enthalten in  |t ScienceDirect. [Elsevier journals]. [Cell Press journals collection]  |d Amsterdam : Elsevier, 2016  |g 56(2019), 2, Seite 96-101  |h Online-Ressource  |w (DE-627)86945241X  |w (DE-600)2869964-6  |w (DE-576)477034438  |7 nnas  |a What's new in consolidation therapy in AML? 
773 1 8 |g volume:56  |g year:2019  |g number:2  |g pages:96-101  |g extent:6  |a What's new in consolidation therapy in AML? 
856 4 0 |u https://doi.org/10.1053/j.seminhematol.2018.08.005  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S0037196318301069  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20200121 
993 |a Article 
994 |a 2019 
998 |g 1015101798  |a Müller-Tidow, Carsten  |m 1015101798:Müller-Tidow, Carsten  |d 910000  |d 910100  |e 910000PM1015101798  |e 910100PM1015101798  |k 0/910000/  |k 1/910000/910100/  |p 3  |y j 
998 |g 1149855606  |a Jaramillo Segura, Sonia  |m 1149855606:Jaramillo Segura, Sonia  |d 910000  |d 910100  |e 910000PJ1149855606  |e 910100PJ1149855606  |k 0/910000/  |k 1/910000/910100/  |p 2 
998 |g 129025380  |a Schlenk, Richard Friedrich  |m 129025380:Schlenk, Richard Friedrich  |d 910000  |d 910100  |e 910000PS129025380  |e 910100PS129025380  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1687942323  |e 3577796146 
BIB |a Y 
JSO |a {"physDesc":[{"extent":"6 S."}],"recId":"1687942323","person":[{"role":"aut","given":"Richard Friedrich","family":"Schlenk","display":"Schlenk, Richard Friedrich"},{"display":"Jaramillo Segura, Sonia","family":"Jaramillo Segura","role":"aut","given":"Sonia"},{"role":"aut","given":"Carsten","family":"Müller-Tidow","display":"Müller-Tidow, Carsten"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"recId":"86945241X","disp":"What's new in consolidation therapy in AML?ScienceDirect. [Elsevier journals]. [Cell Press journals collection]","origin":[{"dateIssuedDisp":"[2016?]-","dateIssuedKey":"2016","publisherPlace":"Amsterdam","publisher":"Elsevier"}],"type":{"media":"Online-Ressource","bibl":"edited-book"},"language":["eng"],"title":[{"title":"ScienceDirect","title_sort":"ScienceDirect","partname":"[Elsevier journals]"}],"corporate":[{"display":"Elsevier Scientific Publishing Company","role":"isb"}],"pubHistory":["2016 [?]-"],"name":{"displayForm":["Elsevier Science"]},"part":{"volume":"56","year":"2019","issue":"2","extent":"6","text":"56(2019), 2, Seite 96-101","pages":"96-101"},"id":{"zdb":["2869964-6"],"eki":["86945241X"]}}],"origin":[{"dateIssuedDisp":"2019","dateIssuedKey":"2019"}],"note":["Available online 29 August 2018","Gesehen am 21.01.2020"],"type":{"bibl":"chapter","media":"Online-Ressource"},"language":["eng"],"title":[{"title":"What's new in consolidation therapy in AML?","title_sort":"What's new in consolidation therapy in AML?"}],"name":{"displayForm":["Richard F. Schlenk, Sonia Jaramillo, Carsten Müller-Tidow"]},"id":{"doi":["10.1053/j.seminhematol.2018.08.005"],"eki":["1687942323"]}} 
SRT |a SCHLENKRICWHATSNEWIN2019 

Ähnliche Einträge